Neuphoria Therapeutics Inc Market Cap ($16.18 Million)
Market Cap & Net Worth: Neuphoria Therapeutics Inc (NEUP)
Neuphoria Therapeutics Inc market cap. Neuphoria Therapeutics Inc (NASDAQ:NEUP) has a market capitalization of $16.18 Million ($16.18 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25597 globally and #5410 in its home market, demonstrating a -11.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuphoria Therapeutics Inc's stock price $2.99 by its total outstanding shares 5411334 (5.41 Million). Also see Neuphoria Therapeutics Inc (NEUP) cash conversion ratio for how efficiently the company converts equity into cash flow.
Neuphoria Therapeutics Inc Market Cap History (2024–2026)
Neuphoria Therapeutics Inc market cap history from 2024 to 2026. Data shows change from $18.56 Million to $16.18 Million (-15.76% CAGR). Check Neuphoria Therapeutics Inc stock quote for real-time trading data and today's change.
Index Memberships
Neuphoria Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #713 of 976 |
Weight: Neuphoria Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuphoria Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuphoria Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Neuphoria Therapeutics Inc (NEUP) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
13.78x
Neuphoria Therapeutics Inc's market cap is 13.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $21.00 Million | $15.65 Million | -$369.63K | 1.34x | N/A |
| 2026 | $16.18 Million | $1.17 Million | -$13.45 Million | 13.78x | N/A |
Competitor Companies of NEUP by Market Capitalization
Companies near Neuphoria Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Neuphoria Therapeutics Inc for a full breakdown of the balance sheet.
Key companies related to Neuphoria Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Neuphoria Therapeutics Inc (2024–2026)
Market capitalization of Neuphoria Therapeutics Inc from 2024 to today. Between 2024 and today, Neuphoria Therapeutics Inc's market cap moved from $18.56 Million to $ 16.18 Million, with a yearly change of -15.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.18 Million | -22.94% |
| 2025 | $21.00 Million | +13.12% |
| 2024 | $18.56 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Neuphoria Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.18 Million USD |
| MoneyControl | $16.18 Million USD |
| MarketWatch | $16.18 Million USD |
| marketcap.company | $16.18 Million USD |
| Reuters | $16.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also deve… Read more